PubMed Health⌕ Search

PubMed · 3315591

Left ventricular function after anisoylated plasminogen streptokinase activator complex.

Abstract

Limitation of the reduction in left ventricular function after acute myocardial infarction is an important indicator of benefit following thrombolytic therapy. Therefore, left ventricular function was studied by radionuclide ventriculography in 91 patients entering 3 separate studies of anisoylated plasminogen streptokinase activator complex (APSAC) administered within 4 hours of acute myocardial infarction. Global left ventricular ejection fraction was measured at 10 days and at 6 months to assess early and late effects of therapy, with particular emphasis on the timing of treatment and the site of infarction. Successful therapy with APSAC in anterior infarction resulted in preservation of left ventricular function at 10 days. The magnitude of benefit declined with increasing symptom duration before treatment, and was maintained at 6 months in those patients without reocclusion. The benefit of successful therapy was less marked in the inferior infarct group at 10 days. By 6 months, no significant benefit was detected because of an increase in ejection fraction in the placebo and occlusion or reocclusion group with inferior infarction. Early therapy results in greater preservation of left ventricular function, and recovery of function may be more rapid than with later treatment. More emphasis on early administration of thrombolytic therapy is indicated.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Been, A L Muir, D P de Bono. 1987. Left ventricular function after anisoylated plasminogen streptokinase activator complex.. https://doi.org/10.2165/00003495-198700333-00034

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Plasminogen activators: a comparison.

Thrombolytic drugs play a crucial role in the management of patients with acute myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, acute thrombosis of retinal vessel, extensive coronary emboli, and peripheral vascular thromboembolism. Recognition of the importance of fibrinolytic system in thrombus resolution has resulted in the development of different fibrinolytic agents. Now a days several newer plasminogen activators with different pharmacokinetic and pharmacodynamic properties have been developed to treat thrombotic disease, which are fibrin specific with prolonged half-life and can be administered as a single bolus.

Anistreplase↗

Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.

PURPOSE: Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant tissue plasminogen activator (rt-PA). MATERIAL AND METHODS: Data were obtained from the Premier Perspective Database, a broad clinical database that contains information on inpatient medical practices and resource use. The study population included all patients hospitalized in 1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted from the database, and are expressed as mean +/- SD. RESULTS: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared with a rate of 1.5% in the rt-PA PAO group (P = .087) and 1.9% in the rt-PA DVT group (P = .175). The in-hospital mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P = .026), but a similar finding in the DVT subgroup did not achieve statistical significance (4% vs 9.8%; P = .069). While pharmacy costs were greater in the urokinase-treated group (US 5472 dollars +/- US 5579 dollars vs US 3644 dollars +/- US 6009 dollars, P < .001; PAO subgroup, US 11,070 dollars +/- US 15,409 dollars vs US 6150 dollars +/- US 12,398 dollars, P = .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group. CONCLUSION: There were significant differences in outcome in patients with PAO and DVT who received treatment with urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.

Anistreplase↗